Download Files:
PD-166793
$110 – $895
Products Details
Product Description
– PD-166793 is a potent, selective, orally active and wide‐broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and MMP-13 (IC50=4, 7, and 8 nM, respectively) and micromolar potency vs MMP-1, -7 and -9 (IC50=6.0, 7.2, and 7.9 μM, respectively). PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure[1][2][3].
Web ID
– HY-107428
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C17H18BrNO4S
References
– [1]O’Brien PM, et, al. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem. 2000 Jan 27;43(2):156-66.|[2]Kaludercic N, et, al. Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther. Spring 2008;26(1):24-37.|[3]Chancey AL, et, al. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation. 2002 Apr 23;105(16):1983-8.
CAS Number
– 199850-67-4
Molecular Weight
– 412.30
Compound Purity
– 99.45
SMILES
– CC(C)[C@@H](C(O)=O)NS(=O)(C1=CC=C(C2=CC=C(Br)C=C2)C=C1)=O
Clinical Information
– No Development Reported
Research Area
– Cardiovascular Disease
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– MMP
Isoform
– MMP-1;MMP-13;MMP-2;MMP-3;MMP-7;MMP-9
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
